Ozempic and sister drug Wegovy—which has been approved by the FDA for chronic weight management—are based on a molecule called semaglutide, which mimics the structure of a hormone that ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Ozempic is based on a naturally occurring human hormone called ... Its active ingredient is a molecule called semaglutide, which mimics the structure of this GLP-1 hormone and activates its ...

In July, Roche also reported strong results from its small molecule oral drug known as CT-996, with participants experiencing an average of 7.3% weight loss, compared to 1.2% for the placebo group.

Researchers have been testing Ozempic's superpowers on chronic diseases beyond diabetes and obesity, such as colorectal cancer, osteoarthritis, drug and alcohol addiction and brain disorders.

Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and ... outside of Copenhagen is even designed to mimic the winding structure of an insulin molecule.

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug that made it onto the market outside the company's approved supply chain.